2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2404

Implications of a Positive Patellar Bulge Sign of Knee Joint Effusion in Patients with Osteoarthritis: Association with MRI Signs of Inflammation and with Increased Rate of 5-Year Total Knee Arthroplasty. Data from the Osteoarthritis Initiative
Abstract Number: 2405

Knee Sounds May Predict Osteoarthritis Severity, Symptoms and Function: Pilot Investigation Toward a Novel Dynamic Imaging System
Abstract Number: 2406

The 2011 Fibromyalgia (FM) Criteria Are Helpful in Identifying Central Sensitization in Knee Osteoarthritis
Abstract Number: 2407

Comparison of Knee Osteoarthritis Treatment in the Non-Obese Versus Obese Populations Across Different Medical Specialties
Abstract Number: 2408

The Quality of Community-Based Osteoarthritis Care Can be Improved. Results from a Systematic Review and Meta-Analysis
Abstract Number: 2409

Factors Associated with Physical Therapy Use in Osteoarthritis of the Knee: Results from a Population-Based Study
Abstract Number: 2410

Report from the International Consortium of Health Outcome Measurement Hip and Knee Osteoarthritis Working Group: Consensus on an International Standard Set of Outcomes Measures for Patients with Hip or Knee Osteoarthritis.
Abstract Number: 2411

Patient Preference for Using Technology to Track and Self-Manage Osteoarthritis
Abstract Number: 2412

Assessment and Comparison of Responsiveness of Four Patient Reported Outcome Measures to Assess Physical Function in Patients with Knee Osteoarthritis: WOMAC-PF Subscale Responds Best
Abstract Number: 2413

Contributors to Walking Disability in People with Osteoarthritis: Results from a Population-Based Cohort
Abstract Number: 2414

High-Intensity Versus Low-Intensity Physical Activity or Exercises in Patients with Hip or Knee Osteoarthritis: A Meta-Analysis
Abstract Number: 2415

Use of Plasma Exchange for Children Hospitalized with ANCA-Associated Vasculitis in the United States
Abstract Number: 2416

Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Pediatric Patients from Six to Less Than Eighteen Years of Age with Juvenile Idiopathic Arthritis
Abstract Number: 2417

Induction and Maintenance of Remission By Etanercept in Enthesitis Related Arthritis JIA-Patients
Abstract Number: 2418

Pediatric Enthesitis-Related Arthritis: Variation in Disease Characteristics and Treatments Among 5 Large Centers

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].